Liver cancer hope: triple therapy shows promise in early trial
NCT ID NCT07543510
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of low-dose bevacizumab and atezolizumab (immunotherapy drugs) plus targeted chemotherapy delivered directly to the liver (TACE-HAIC) as a first treatment for people with unresectable hepatocellular carcinoma. About 38 participants will receive this approach to see if it shrinks tumors and delays progression. The goal is to improve on current standard therapy, which has limited effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab and atezolizumab (immunotherapy and anti-angiogenic drugs) combined with chemotherapy delivered directly to the liver
- What this could lead to
- If successful, this combination could improve tumor shrinkage and delay cancer progression in people with advanced liver cancer that cannot be surgically removed.
- What could go wrong
- This is a small, early-phase trial (38 people) with no comparison group, so results may not be definitive. The combination also carries risks like bleeding, liver damage, and immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATEZOLIZUMAB PLUS BEVACIZUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?